观点联合利华

The basic problem with Unilever’s £50bn healthcare bid

Whether or not it buys GSK’s consumer health unit, the company is on the hunt for a big acquisition

Unilever, as we know from Terry Smith, is keen on purpose. And the purpose of its sudden announcement of a strategic rethink and organisational overhaul was very clear: damage limitation.

There’s no use crying over spilled mayonnaise, but the consumer goods group finds itself in a bit of a pickle.

Smith’s broadside last week about purpose-driven condiments and a management team “obsessed with publicly displaying sustainability credentials” highlighted broader investor dissatisfaction with Unilever’s lacklustre performance.

您已阅读12%(526字),剩余88%(3793字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×